Dottorato in Fisiopatologia Medica

Contatti

Tesi di dottorato

Research Topic

Cardiovascular Risk Profile in Patients with Oncological disease and Chronic Diseases

Experimental Plan

Cardiovascular adverse events (CVAEs) are linked to Carfilzomib (K) therapy in multiple myeloma (MM). Despite the inference about cardiotoxic burden related to K, no validated management protocols on cardiovascular risk assessment and follow-up are available, making it challenging to assess the individual cardiovascular risk profile and to estimate the probability of CVAEs in a real-life setting. Furthermore, major predictors of CVAEs in MM are unclear.

Objectives

1. To assess the incidence in a ‘real-life’ setting of cardiovascular and hypertensive events in a cohort of MM patients during K therapy, prospectively followed;
2. To investigate major predictors of CVAEs in MM patients undergoing potentially cardiotoxic treatment and to assess the subclinical organ damage caused by anti-myeloma drugs;
3. To identify a multimodality assessment protocol for the cardiovascular risk estimation in MM patients before and during K therapy.

This prospective study is conducted at the third level Hypertension Unit of ‘Città della Salute e della Scienza’ Hospital in Turin. Patients with MM scheduled to K therapy are consecutively enrolled, and followed until the end of treatment.

Attività di ricerca

 

PhD 1^st year

D-day : January 24

Lessons and seminars:

11/07/23 How to write a scientific paper - Prof. R.Granata

20/06/23 Scientific presentations - Prof. B. Bussolati

13/07/23 How to set up an in vivo experimental model - Prof. S. Bruno

20/07/23 Regression models: from the linear model to the generalised linear models. Interpretation of interactions between predictors - Prof. M. Maule

27/06/23 Physiopathology of diabetic nephropathy - Prof. G. Gruden

04/07/2023 Update on physiology of hypertension - Prof. F. Veglio

PhD 2^st year

D-day : January 25

Lessons and seminars:

31/05/24- Patophysiological basis of laboratory tests - Prof. G. Mengozzi

21/05/24 - Metabolomics and steroid: from antidoping to clinical biochemistry using mass spectrometry - Prof. E. Ghigo / Dr. F. Ponzetto

14/05/24 - Pathophysiological basis of diabetic nephropathy. Prof. G. Gruden

08/07/24 - Antimicrobial resistance: mechanism and detection methods - Prof. C. Costa

PhD 3^rd year

Lessons and seminars:

23/06/25 Pathophysiological and biomarker pathways of cardiovascular emergencies - Prof. F. Morello

14/07/2025 Genetic testing and functional genomics in the diagnostic workflow of rare diseases - Prof. T. Vaisitti

24/07/25 Cardiac electric physiopathological properties - Prof. G. De Ferrari

21/07/2025 Therapeutic strategies for liver transplant - Prof. R. Romagnoli

10/09/2025 Current and future directions of kidney transplantation - Prof. L. Biancone

11/09/2025 Cancer survivors: pathophysiology of late-effects and implication for translational application - Prof. E. Arvat

Publications

Astarita A, Mingrone G, Airale L, Colomba A, Catarinella C, Cesareo M, Vallelonga F, Paladino A, Bruno G, Leone D, Gay F, Bringhen S, Veglio F, Milan A. Validation of the HFA-ICOS Score for Carfilzomib-Induced Cardiotoxicity in Multiple Myeloma: A Real-Life Perspective Study. Cancers(Basel). 2025 Jul 15;17(14):2353.

Fanelli E, Picca G, Airale L, Astarita A, Mingrone G, Catarinella C, Votta S, Colomba A, Cesareo M, Leone D, Paladino A, Rabbia F, Bringhen S, Gay F, Veglio F, Milan A, Vallelonga F. Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma. Hypertens Res. 2025 Apr ;48(4):1554-1563.

Colomba A, Airale L, Lasagno A, Mingrone G, Astarita A, Vallelonga F, Leone D, Sanapo M, Paladino A, Novello F, Bringhen S, Gay F, Veglio F, Milan A. The Emerging Role of Left Atrial Strain in Cardiovascular Risk Stratification for Multiple Myeloma Patients Undergoing Carfilzomib Therapy. Cancers (Basel). 2025 Jul 17;17(14):2375.

Colomba A, Astarita A, Mingrone G, Airale L, Catarinella C, Vallelonga F, Leone D, Cesareo M,Paladino A, Bringhen S, Gay F, Pedrizzetti G, Veglio F, Milan A. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. Cancers (Basel), 2024 Sep 4;16(17):3081.

Astarita A, Mingrone G, Airale L, Cesareo M, Colomba A, Catarinella C, Leone D, Gay F, Bringhen S, Veglio F, Milan A, Vallelonga F. Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study. Cancers (Basel). 2023 Feb 2;15(3):955.

Mingrone G, Astarita A, Colomba A, Catarinella C, Cesareo M, Airale L, Paladino A, Leone D,Vallelonga F, Bringhen S, Gay F, Veglio F, Milan A. Patients with Very High Risk of  Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience. Cancers (Basel). 2023 Feb 10, 15(4):1149.

Astarita A, Mingrone G, Airale L, Vallelonga F, Covella M, Catarinella C, Cesareo M, et al. Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction. Cancers (Basel), 2021 Apr 1;13(7):1631.

Mingrone G, Astarita A, Airale L, Maffei I, Cesareo M, Crea T, Bruno G, Leone D, Avenatti E, Catarinella C, Salvini M, Cetani G, Gay F, Bringhen S, Veglio F, Vallelonga F, Milan A. Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. Front Cardiovasc Med. 2021 Apr 21;8:645678.

ORCID: orcid.org/0000-0003-4436-5231